Delivery of viral vectors to tumors in the brain is a challenge, especially via systemic administration, which is key to targeting the invasive margins of malignant glioma and the multiple foci of metastatic disease. Like for other cancer therapeutics, the blood-brain barrier or even the bloodtumor barrier significantly limits delivery and efficacy. Bloodbrain barrier disruption (BBBD) is one strategy for transiting the cerebrovasculature. G47D is a third-generation oncolytic replication-competent herpes simplex virus (HSV) vector, containing deletions of the g34.5 and a47 genes and an inactivating LacZ insertion in UL39 (ICP6). Intracarotid artery delivery of G47D after BBBD with 25% mannitol significantly extended the life of nude mice bearing intracerebral human MDA-MB-435 breast tumors, whereas, G47D injection contralateral to the tumor, in the absence of mannitol or mannitol alone had no effect on survival. G47D replication was extensive after BBBD, as visualized by X-gal staining. Staining of peripheral organs, lung and liver, was minimal and not altered by BBBD. This is the first demonstration of intracarotid arterial delivery of oncolytic HSV vectors and antitumor efficacy in a mouse model and opens the door to the use of mouse syngenic tumor models and transgenic/ knockout animals. Gene Therapy (2005) 12, 647-654.
Introduction
Oncolytic viruses, in particular herpes simplex virus (HSV), are a new strategy for cancer therapy, where viral replication and cytotoxicity are targeted to tumor cells. 1 Replication-competent oncolytic HSV-1 vectors have been developed with mutations in genes affecting nucleotide metabolism, neuropathogenicity, and immune-evasiveness, which are efficacious yet safe in animal models and humans.
2 G207 was the first oncolytic HSV vector tested in humans in the US. 3 It has deletions in both copies of the g34.5 gene, the major determinant of HSV neurovirulence, 4 and an insertion of Escherichia coli LacZ into UL39, inactivating the large subunit of ribonucleotide reductase (ICP6).
5
G47D is a thirdgeneration vector derived from G207, with an additional deletion of ICP47 and the promoter region of US11. 6 This deletion places the late US11 gene under control of the immediate-early ICP47 promoter, which enhances the growth of g34.5-deficient mutants by blocking the shutoff of protein synthesis. 7 In addition, ICP47 blocks MHC class I presentation in infected cells 8 and its deletion should enhance immune recognition of infected cells. 6 G47D is more efficacious than G207 in a number of subcutaneous tumor models, in immune-deficient and -competent mice, yet was similarly nontoxic after intracerebral injection. 6 The most common malignant tumors in the brain are metastases, with up to 50% of cancer patients eventually developing brain metastases. 9 Melanoma, while not the most common cancer, has the greatest likelihood to metastasize to the brain with B50% clinically diagnosed and up to 80% at autopsy. 10 In lung cancer, brain metastases are common with about 10% of patients presenting with small-cell lung cancer having brain metastases and rising to B40% at autopsy. 11 Other cancers metastasizing to the brain include breast with 10-20% of patients, 12 followed by renal and colorectal. 13 The percentage of patients where their primary tumor metastasizes to the brain has been increasing over the last two decades, related in part to the increased efficacy of current treatments for primary disease and the associated increased survival. 14, 15 We previously established a model of breast cancer brain metastases with intracerebral implantation of human breast cancer cells. Direct intratumoral injection of G207 into intracerebral MDA-MB-435 tumors was efficacious in significantly extending survival. 16 Metastases to the brain frequently result in severe and debilitating neurological complications (ie, paralysis, seizures, and impaired cognition), which have a large impact on a patient's quality of life. Radiotherapy is often the standard of care; however, it is only palliative with minimal effect on survival, 17 and often is associated with significant morbidity especially in the young and elderly. Surgery can extend survival, however it is dependent upon the lesions being resectable, and is often limited to single or a few lesions. 18 For most patients, there have been limited improvements in treatment, with median survival from 3 to 6 months and many patients dying of neurologic causes. 19 Treatment of metastatic tumors in the brain is more complicated than in the periphery because of the blood-brain barrier (BBB), which limits systemic delivery of chemotherapy and biologics.
The BBB consists of brain endothelial cells, with unique properties compared to peripheral endothelial cells, pericytes, astrocytic end-feet, and neuronal processes. 20 Important features of brain endothelial cells are their high resistance tight junctions, the absence of pinocytotic vesicles and fenestrations, and the paracrine influence of the other cell types. 21 Even blood vessels within brain tumors, with a disrupted barrier, remain much less permeable than vasculature in the periphery. Disruption of the BBB, for purposes of drug delivery, has been achieved by intracarotid infusion of hypertonic solutions such as mannitol and arabinose, 22 inflammatory mediators such as leukotrienes or histamine, or bradykinin and its agonist RMP-7. 23 Both mannitol and RMP-7 have been used in the clinic for blood-brain barrier disruption (BBBD) to enhance brain tumor chemotherapy. 24, 25 In a direct comparison, hypertonic mannitol was found to be better than bradykinin for drug delivery to rat intracerebral xenografts. 26 BBBD even enhanced the delivery of oncolytic HSV to brain tumors in rat models. 27, 28 For the most part, BBBD tumor therapy studies have been performed in rats because of size considerations. However, mice have a number of advantages for studying brain tumor therapy: (1) a variety of syngeneic tumor models; (2) spontaneously arising tumors in transgenic models; and (3) knockout mice to study the role of genetic alterations on therapeutic efficacy.
Results

BBBD after intracarotid delivery
Osmotic disruption of the BBB is one way to facilitate transfer of molecules, including viral vectors, from the circulation to the brain parenchyma. Intracarotid arterial infusion of hypertonic solutions, such as mannitol or arabinose, has been successfully used for osmotic BBBD in experimental animals and humans. 22 A rapid test to assess BBBD is infusion of Evans blue dye, which binds to albumin producing a 68 kDa compound that does not cross the BBB. 29 FVB mice were infused with PBS, 25% mannitol or 1.8 M arabinose, followed immediately by Evans blue dye (Figure 1 ), and killed 5 min later. The ipsilateral, but not contralateral, hemisphere was stained after mannitol or arabinose (Figure 2b and c) and no staining was observed after PBS ( Figure 2a ). Arabinose resulted in increased BBBD compared to mannitol as detected by Evans blue staining ( Figure 2c versus b) ; however, it was quite toxic. In arabinose infused nude mice, all animals (six of six) were sick or dead within 48 h of treatment, whereas, no animals (zero of eight) were affected after mannitol treatment. Figure 1 Intracarotid artery injection. A longitudinal incision is made on the neck (left). After exposing the carotid sheath, the common, internal, and external carotid are dissected, and a microclamp is used to clamp the external carotid and the proximal part of the common carotid (right). Injections are given through a 30 G needle punctured upward into the common carotid; note Evan's blue dye being injected into the artery (right).
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Intracarotid artery delivery of G47D to intracerebral MDA-MB-435 breast tumors
To test the effect of BBBD on the delivery of oncolytic HSV vectors to metastatic tumors in the brain, we used a previously described model of intracerebrally implanted human MDA-MB-435 breast cancer cells. 16 These cells are very sensitive to oncolytic HSV cytotoxicity so that in vitro infection with G47D at an MOI of 0.01 results in total cell death within 4 days. 30 G47D expresses E. coli LacZ under the HSV ICP6 promoter so that infected cells can be detected with X-gal histochemistry. MDA-MB-435 cells were implanted in the right frontal lobe of nude mice, tumors established, and G47D injected after PBS or BBBD (25% mannitol). Mice were killed at different days after injection, brains dissected out and sectioned, and then stained with X-gal. There were very few, if any X-gal-positive cells after G47D injection without BBBD (with PBS) (Table 1) , with the brain at day 14 exhibiting some of the most extensive labeling (Figure 3 , right). In contrast, after BBBD (with mannitol), there was extensive staining of cells within the tumor at multiple foci ( Figure  3 , left), with few X-gal-positive staining cells in normal brain, except for cells on the surface of the brain, likely meningeal cells, especially early after injection (ie, Figure  3 , left d5). The degree of X-gal staining generally increased within the first week post-treatment and 
Each row represents a single mouse, and the mice came from three separate experiments. The number of +'s represents the level of Xgal staining, with the tumor at d19 (+mannitol) in Figure 3 having ++++; ND: not determined.
Oncolytic HSV therapy of brain tumors after BBBD R Liu et al remained for 19 days, as long as we looked (Table 1) . There was staining of only a few scattered cells in the lungs and liver ( Figure 4 ) in a subset of the animals that did not seem to vary with or without BBBD ( Table 1) .
Treatment of intracerebral MDA-MB-435 breast tumors after intracarotid artery delivery of G47D
Intracarotid arterial delivery of G47D after BBBD had a large effect on the health of mice bearing intracerebral MDA-MB-435 tumors. Examples of mice 10 days after treatment are illustrated in Figure 5 . Mice that received G47D without BBBD ( (Figure 6 ). While G47D slightly extended survival compared to mock, the difference was not significant.
Discussion
Systemic delivery of viral vectors for cancer therapy is an important hurdle to be overcome for the successful application of these agents in the clinic. Intravascular injection is a simpler, less invasive, and cheaper procedure than direct local delivery to the tumor, does not require anatomical localization of the tumor, and has the potential to reach all tumor foci in metastatic disease. Compared to rodent tumor models, the large size of humans and their tumors makes local delivery of vectors and broad tumor distribution more difficult. The brain provides further challenges, especially via systemic administration, which is key to targeting the invasive margins of malignant glioma and the multiple foci of metastatic disease. The interaction between brain tumors, normal brain, vasculature, and neovasculature is complex. In malignant gliomas and metastatic tumors, were implanted stereotactically into the right frontal lobe. After 5 days, the mice were treated with 25% mannitol (30 ml/g/min for 20 s) and then 50 ml of G47D (1 Â 10 7 pfu) for 1 min by intracarotid injection. The mice were killed at the days indicated, brains dissected, sectioned frozen, and then stained with X-gal. There was extensive X-gal staining at multiple locations in brain tumors after G47D injection with BBBD (left, + mannitol). This was in contrast to staining of brain tumors after G47D injection without BBBD (right), with the d14 brain having the most extensive X-gal staining of this group. X-gal staining was confined to the region of the tumor after BBBD. This does not permit differentiation between staining of tumor or normal cells within the tumor mass. There were scattered positive cells on the surface of the brain, which may have been in tumor cells that got into the cerebrospinal fluid (CSF) or ependymal cells.
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the BBB is leaky, leading to edema and contrast enhancement in magnetic resonance imaging (MRI).
31-33
The BBB or even the blood-tumor barrier significantly limits vector delivery and efficacy, as for other cancer therapeutics. 34 As opposed to drugs and other biologics, there are additional obstacles for viral vectors after intravascular delivery, including their large size and specific interactions with blood components, cells of the vasculature and the immune system. 35, 36 Oncolytic viruses such as HSV have a large advantage over drugs and even replication-deficient viral vectors for systemic delivery in that even if most of the input vector does not reach the tumor, its ability to replicate and be amplified 4 cells) were implanted stereotactically into the left or right front lobe of the brain. After 5 days, when tumors were established, the right carotid artery was exposed, the external carotid clamped and a needle inserted into the common carotid. G47D was injected immediately after 25% mannitol (BBBD) or PBS, and mice were killed 10 days later. Left, mouse with ipsilateral tumor treated with G47D without BBBD (PBS). Middle, mouse with ipsilateral tumor treated with G47D with BBBD (mannitol). Right, mouse with contralateral tumor treated with G47D with BBBD (mannitol). Note the emaciated appearance of the mice on the left and right. Figure 6 Treatment of intracerebral breast tumors after BBBD. Human MDA-MB-435 breast carcinoma cells were implanted stereotactically into the right frontal lobes of nude mice. After 5 days, mice were treated with G47D (1 Â 10 7 PFU; n ¼ 9) after mannitol (BBBD) or PBS (n ¼ 8), or mock (PBS/10% glycerol after mannitol; n ¼ 9). The mice treated with G47D after BBBD survived significantly longer than mock (Po0.0001, logrank test) or G47D without BBBD (Po0.02, logrank test). There was no significant difference in survival between G47D after PBS and mock after BBBD.
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We report here the first demonstration of intracarotid delivery of oncolytic HSV vectors to tumors in the brains of mice after BBBD and the therapeutic benefit of such delivery. Only a few studies have examined BBBD in mice and none in tumor-bearing animals, probably because of the small size of the carotid artery. 37, 38 In general, the BBB permeability in mice is very similar to rats for a range of passively diffused and transported drugs. 39 For osmotic BBBD, we tested intracarotid infusion of 1.8 M arabinose 37 or 25% mannitol. 29 While arabinose resulted in more extensive BBBD than mannitol, as illustrated by Evans blue dye extravasation, it proved to be too toxic to use for therapeutic studies. Previous studies did not find any neurologic dysfunction or long-term health effects associated with using arabinose for BBBD in mice, 37 ,38 and we do not know why it was so toxic in our studies.
A careful analysis of the in vivo biodistribution of HSV-1 after intracarotid injection of hrR3 in rats with 9L intracerebral tumors has been performed using 111 Inoxine labeled virus. 40 As expected, most of the virus went to the liver, 2.6%/g, followed by the lung, spleen, and kidney. In this model, there was only a small increase in the amount of virus in the brain tumor after BBBD with RMP7 (0.1 versus 0.17%/g). 40 This small difference may have been due to the tumor model and the fact that this assay does not distinguish infectious from non-infectious virus or infected cells from extracellularly trapped virus. Interestingly, there was a 4two-fold decrease in the liver after BBBD. In a separate study using ultraviolet-inactivated 35 S labeled HSV-1 in non-tumor-bearing rats, BBBD with mannitol markedly increased the amount of virus in the ipsilateral hemisphere (normal brain), with only a minor increase in the liver. 41 We found only a limited number of G47D-infected cells in the lungs or liver, but LacZ expression would only be maintained in cells with replicating virus.
There have been a number of prior studies examining intracarotid delivery of replication-deficient adenovirus vectors and oncolytic HSV vectors to tumors in the brain, usually after BBBD, and all performed in rats. 42 In general, these studies indicate that the distribution and number of infected cells is greater in the tumor than in normal brain, suggesting that the blood-tumor barrier is more permissive to viral transit after disruption than the BBB. 27, 28 We also found that almost all of the X-gal staining after G47D intracarotid artery injection occurred in the tumor, even in the absence of BBBD, although the degree of tumor labeling was considerably increased after BBBD. While we did not undertake a detailed analysis of infected cell phenotypes, one would only expect to see X-gal staining of individual infected normal cells, not foci as with tumor cells, and only within a few days of infection. 43 Intravascular delivery of oncolytic HSV to tumors in the brain can be compromised by innate immune responses and serum factors even before transiting the BBB. 36 For example, complement depletion with cobra venom factor results in significantly increased numbers of oncolytic HSV-infected brain tumor cells after intracarotid delivery with RMP7 BBBD. 44 Cyclophosphamide, which depresses innate IgM levels and complement activation in rats, as well as other immune functions, also enhanced viral transduction of intracerebral tumors after intracarotid delivery with BBBD and extended the survival of U87dEGFR glioma-bearing nude rats. 45 We have not examined the impact of complement activation in our model, which might have resulted in even greater efficacy, although the complement pathway in mice is somewhat different from rats. 44, 46, 47 After gaining access to the brain parenchyma, the ability of G47D to replicate specifically in tumor cells and spread throughout the tumor is apparent from continued labeling of the tumor for at least 19 days after injection. We have previously detected extensive X-gal staining of G207-infected human subcutaneous tumors at 15 and 24 days after treatment, 5, 48 while others have detected infectious HSV up to 31 days postinfection. 49 Virus replication and spread in situ is a strength of this approach, which can overcome some of the difficulties in transiting the BBB. Intracarotid artery delivery of oncolytic HSV vectors after BBBD holds promise for the treatment of brain tumor patients, especially those with multiple tumor foci or in surgically inaccessible locations. Mice provide an excellent model for cancer therapeutic studies and the ability to perform intracarotid artery injections in mice allows us to test this approach in a variety of syngeneic tumor models, including in transgenic and knockout mice.
Materials and methods
Viruses and cells G47D was constructed as described, 6 and contains deletions of both copies of the g34. 5 gene, an inactivating insertion of E. coli LacZ into the ICP6 locus, and a deletion of ICP47 and the US11 promoter. Purified virus stocks 50 in Dulbecco's phosphate-buffered saline (D-PBS)/10% glycerin were provided by MediGene Inc. (San Diego, CA, USA). Viruses were titered by plaque assay on Vero cells.
Vero (African green monkey kidney) cells (ATCC) and human MDA-MB-435 breast cancer cells 51 (obtained from the Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC, USA) were cultured in Dulbecco's modified Eagle's medium (DMEM) with glucose (4.5 g/l) (Mediatech Inc., Herndon, VA, USA) supplemented with 10% calf serum (Hyclone Laboratories, Logan, UT, USA) at 37.51C in 5% CO 2 .
Animal studies
In all, 6-week-old female Balb/c nude and FVB mice were purchased from the National Cancer Institute (Frederick, MD, USA) and caged in groups of five or less. For injections and surgical procedures, each mouse was anesthetized with an intraperitoneal injection of 0.20-0.25 ml of solution consisting of 86% saline, 9% sodium pentobarbital, and 5% ethyl alcohol. Intracerebral tumors were generated by injecting 5 Â 10 4 MDA-MB-435 cells in 4 ml of serum-free medium stereotactically into the right frontal lobe. The Massachusetts General Hospital Animal Care and Use Committee approved all animal procedures.
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Intracarotid artery injection
The carotid artery (common, internal, and external) was dissected and the external carotid and the proximal end of the common carotid clamped with microclamps. A 30 G needle (connected to PE-10 tubing) was inserted upward into the common carotid ( Figure 1 ) and infusions were made with a SP120p Syringe Pump (WPI, Inc.). The needle was then removed under compression, the clamp removed and the incision closed with 8-0 polypropylene suture (Deklene). The first injection was 200 ml of 25% mannitol (30 ml/g/min; Abbott Laboratories, North Chicago, IL, USA) over 20 s, followed immediately by 40 ml Evan's blue (Sigma; 20 mg diluted with 1 ml normal saline) or 50 ml G47D (1 Â 10 7 pfu) over 1 min. There is about a 50% loss in virus titer during passage through the tubing. Mice were monitored for health status and were sacrificed when moribund. Less than 5% of mice died from surgical complications. Statistical significance was determined using Statview.
X-gal histochemistry
Mice were euthanized and perfused with Zamboni's fixative (1.8% paraformaldehyde, 7.5% picric acid, 0.19% EGTA, and 2 mM magnesium chloride, pH 7.3), brains removed, and molded frozen on dry ice. Cryostat sections (20 mm in thickness) were prepared, fixed in 2% paraformaldehyde in PBS (all PBS is pH 7.2) for 10 min, washed two times in PBS, and incubated with PBS containing 2 mM magnesium chloride, 0.01% sodium deoxycholate, and 0.02% Nonidet P-40 (NP-40) at 41C for 10 min. They were stained using substrate solution (PBS containing 1 mg/ml 5-bromo-4-chloro-3-indolyl-b-D-galactopyranoside (X-Gal), 5 mM potassium ferricyanide, 5 mM potassium ferrocyanide, 2 mM magnesium chloride, 0.01% sodium deoxycholate, and 0.02% NP-40) at 341C for 4 h, then washed once with water, and twice with PBS containing 2 mM EDTA. Sections were counterstained with hematoxylin and eosin before mounting.
